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Abstract: Myelination is critical for the normal functioning of the central nervous system (CNS)
in vertebrates. Conditions in which the development of myelin is perturbed result in severely
compromised individuals often with shorter lifespans, while loss of myelin in the adult results in a
variety of functional deficits. Although some form of spontaneous remyelination often takes place,
the repair process as a whole often fails. Several lines of evidence suggest it is feasible to develop
strategies that enhance the capacity of the CNS to undergo remyelination and potentially reverse
functional deficits. Such strategies include cellular therapies using either neural or mesenchymal stem
cells as well as molecular regulators of oligodendrocyte development and differentiation. Given the
prevalence of demyelinating diseases and their effects on the quality of life for affected individuals it
is imperative that effective therapies are developed. Here we discuss some of the new approaches to
CNS myelin repair that hold promise for reducing the burden of diseases characterized by myelin loss.
Keywords: demyelination; remyelination; multiple sclerosis; OPCs; oligodendrocytes; MSCs

1. Introduction
There are many forms of demyelinating diseases in humans, and they are often typified by the
loss or dysfunction of oligodendrocytes [1]. Although myelin loss per se is associated with conduction
blocks along myelinated axons that often lead to clinical deficits, it is usually followed by some degree
of axonal dysfunction or loss associated with the accrual of functional disability [2]. Remyelination is a
regenerative process whereby myelin sheaths are restored, and although spontaneous remyelination is
a normal physiological response after most demyelinating conditions [3,4], there is evident heterogeneity
in the extent of remyelination, with an estimated 20–30% of people with multiple sclerosis (MS) showing
extensive remyelination [5]. The study of developmental myelination, pathologic demyelination, and
remyelination has been instrumental in setting the stage for this emerging field and is evidenced by
the amount of work being undertaken to develop remyelinating therapies. Despite having achieved
milestones at developing disease modifying therapies that halt the progression of diseases like MS,
there is a paucity of directed therapies to repair or regenerate myelin [6]. Therefore, there is a need
to understand mechanisms of remyelination and causes of remyelination failure to be able to better
design strategies for enhancing remyelination. Here, we discuss some of these potential strategies,
particularly in relation to myelin biology in health and disease.
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contact, one oligodendrocyte will extend multiple processes that contact multiple axons within a clearly
defined time-window. Some of those processes are rapidly retracted suggesting that some form of
axon selection process takes place. Interestingly, there is only a brief period during which myelination
can take place, and oligodendrocytes are deemed incapable of extending additional internodes once
they mature [30,32]. Those processes that are sustained, generate initial myelin segment domains that
may either grow, remain constant, or shrink. It is now known that many of these changes are the
result of activity-dependent secretion by axons, whereby inhibition of synaptic vesicle exocytosis in
zebrafish resulted in shorter, thinner myelin sheaths [31]. Furthermore, control of the myelin segment
growth is at the level of individual sheaths rather than at the level of oligodendrocyte cell body and is
dependent on local calcium signaling [27–29]. It seems likely that electrical activity within the axon is
important in regulating Ca2+ fluxes and modulating the extent of myelination [33–35]. For example,
blocking electrical activity of retinal ganglion cells through preventing eye opening or following
treatment with the Na+ channel blocker tetrodotoxin (TTX) significantly perturbs myelination of the
optic nerve [33]. Similarly, following toxic demyelination with ethidium bromide, glutamatergic
transmission between axons and OPCs directly modulate remyelination, such that when neuronal
activity is blocked or synaptic transmission inhibited, OPCs do not differentiate into myelinating
oligodendrocytes, but rather remain in a proliferative state [36]. This phenomenon could be responsible
for failure of remyelination in chronic MS lesions.
Recent evidence suggests that myelin production persists throughout life, including changes in
existing internodes, or even generation of new internodes by newly generated oligodendrocytes [37,38].
This form of myelin plasticity could have a direct effect on neuronal plasticity and in turn be critical for
learning and memory. How the wrapping of the myelin sheath actually occurs is not well understood
at a cellular level. Several lines of evidence suggest, however, that both biophysical properties of the
myelin sheath proteins MBP and PLP contribute to selective membrane fusion while changes to the
oligodendrocyte cytoskeleton, particularly the actin network, are essential to facilitate formation of the
compact myelin sheath [39–42].
4. Mechanisms of Remyelination: Can We Recapitulate Developmental Signals?
A major challenge is to understand how our knowledge of developmental myelination can
be utilized to promote myelin repair in the adult CNS. The so-called recapitulation hypothesis has
emerged with the notion that developmental myelination and remyelination, should at least in theory,
have similar processes, with regards to OPC expansion, migration, proliferation, and differentiation
into myelinating oligodendrocytes. Although much of the current literature remains to this date
biased towards development, there are some key findings in support of this hypothesis. For example,
the rate limiting steps in generating new myelin may be at the level of OPC generation, differentiation
or maturation. It is known that the many of the remyelinating oligodendrocytes come from local
OPCs [43,44]. However, recent evidence suggests that neural precursor cells are a major source of
myelinating oligodendrocytes which in some regions such as the rostral corpus callosum, outnumber
those generated from OPCs [45]. In addition, many of the genes upregulated in OPCs following injury
to the white matter resemble those associated with oligodendrocytes during development, such as
Olig2 and Nkx2.2 [46]. One potential complication to using development as a guide to myelin repair
is that the environment of the damaged CNS is significantly different from that in development and
some critical signaling pathways, or the sequence of their expression, may be altered.
5. Insults with Associated Myelin Loss
There are a wide range of conditions in which the development or maintenance of myelin is
compromised, either as a result of direct damage to the myelin sheath, or indirectly as a result of
oligodendrocyte dysfunction or loss (reviewed in [47]). Whatever the underlying cause, myelin
loss is generally associated with significant functional deficits [11,48,49]. One family of myelin
associated diseases are the leukodystrophies, which refers to abnormal white matter. These diseases
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arise as a consequent of genetic defects that affect the generation or survival of oligodendrocytes
and their associated myelin. Many of the leukodystrophies arise during development such
as Pelizaeus-Merzbacher disease (PMD), which is a rare congenital disorder characterized by
hypomyelination and is the result of duplication or missense mutation of the PLP1 gene, eventually
leading to abnormal or reduced myelin formation and oligodendroglial death [50]. Other disorders
of hypomyelination that share similar characteristics with PMD have been characterized, and there
is now close to 14 hereditary leukodystrophies reported in the literature [51]. A variation of the
leukodystrophies is vanishing white matter disease. In this condition myelin appears to form and
is then rapidly lost. The underlying mechanisms mediating vanishing white matter disease are not
well established, although recent data suggests it is associated with changes in both oligodendrocytes
and astrocytes [52,53]. Another congenital disorder of hypomyelination where the main pathology
is in non-olidogendroglial cells is Alexander disease. This disease is caused by mutations in glial
fibrillary acidic protein (GFAP) [54]. In general, because these diseases arise from genetic mutations
directly or indirectly linked to myelin development and/or maintenance, their clinical sequelae are
characteristically devastating with little or no treatment currently available.
The most common adult demyelinating disease of the CNS is multiple sclerosis [55]. MS can
present in a number of different ways and may be a heterogeneous family of related conditions.
The initial cause of MS is unknown. Genetic studies link the major histocampatablity complex
(MHC), that reflects the role of the immune system in the pathology of the disease rather than its
induction. Other risk factors include cigarette smoking, early exposure to viral infections such as
EBV, low vitamin levels such as vitamin D, or loss of critical vitamin cofactors ([56–58], and refer
to [59] for a comprehensive summary of the known risk factors associated with the development
of MS). It seems as though multiple environmental cues may increase susceptibility to MS and
many of these potential risk factors occur during early childhood, even though the disease generally
does not manifest until adulthood. One possible explanation for this temporal separation is that
during childhood and adolescence effective ongoing myelin repair masks the functional expression of
demyelinating pathology. In its most common form, MS is considered to be an autoimmune condition
that initially manifests itself as a relapsing-remitting disease with defined functional deficits from which
individuals usually recover over time. It is understood that much of that initial recovery correlates
with partial remyelination, which despite being refuted/debated for a long time, there is now strong
histological and neuroimaging evidence to suggest there is constant remyelination in MS lesions [60–63].
However, the extent of remyelination seems to vary between people with MS, and even between lesion
location in the same individual, which could in part be due to oligodendrocyte heterogeneity [5,64,65].
Following subsequent attacks, however, recovery is less complete and many individuals go on to
develop chronic functional deficits secondary to progressive axonal loss. Interestingly, remyelination
can usually be identified by the presence of invariably thin myelin sheaths (Figure 3B) [66]. Whether the
progressive forms of the disease have a direct relationship to inefficient or incomplete remyelination
is not clear, but there is evidence from histological studies implicating that migration of OPCs is
affected in more chronic lesions, mainly owing to perturbed expression of extracellular matrix proteins,
such as fibronectin and vitronectin [67–69]. Moreover, the differentiation of OPCs into myelinating
oligodendrocytes is also impaired in chronic and progressive forms of MS [70,71]. The correlation
of functional deficits with localized demyelination comes from imaging and postmortem analyses.
A range of imaging modalities particularly MRI identify areas of white matter damage that can
frequently be correlated with selective functional loss while pathological studies demonstrate areas of
immune cell infiltration and astrocyte activation associated with demyelination. While areas of local
demyelination are clearly a defining characteristic of MS, the precise degree of functional loss directly
applicable to myelin loss rather than local inflammation or axonal damage is unresolved.
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In other CNS insults, myelin loss is not the primary target, rather oligodendrocyte death and
myelin loss is a secondary consequence of the initial insult that contributes to further damage or
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In other CNS insults, myelin loss is not the primary target, rather oligodendrocyte death and
myelin loss is a secondary consequence of the initial insult that contributes to further damage or
dysfunction. For example, in the setting of ischemic stroke, neurons in the ischemic area are primarily
affected, but their loss of viability leads to subsequent loss of myelin. Recent work suggests that this
response is secondary to vesicular release of glutamate from axomyelinic structures, which in turn can
interact directly with the myelin sheaths via NMDA receptors causing elevation of intracellular Ca2+
levels, and myelin decompaction and release [84,85]. A different mechanism by which ischemia causes
elevation of intracellular Ca2+ and subsequent myelin damage is through elevation of extracellular K+ ,
leading to an increase in intracellular H+ and activation of TRPA1 receptors [86]. Likewise, in spinal
cord injury the initial insult results in direct damage to and severing of axons but secondary damage
resulting from infiltration of immune cells and local inflammatory responses contribute to myelin
and oligodendrocyte loss that again compromises the capacity of the tissue to recover/regenerate [87].
In both stroke and spinal cord injury, preventing oligodendrocyte and myelin loss has had a significant
functional benefit for long term recovery [88]. Whether the mechanisms mediating myelin loss in these
conditions are similar to those in diseases such as MS is not fully resolved. Given the heterogeneity
of conditions with associated CNS demyelination, a broad range of different animal models have
been developed to interrogate the pathological mechanisms and use that knowledge to develop
remyelinating strategies.
6. Animal Models of Myelin Loss
A range of different animal models have been developed that are useful for enhancing our
understanding of the mechanisms of demyelination and developing new therapeutic approaches to
treat demyelinating diseases [89]. There are three general categories of animal models: those that
depend on immune mediated demyelination; those that depend on chemical induced demyelination;
and those that use genetic approaches to specifically ablate myelinating cells. Each of the models
has strengths and weaknesses. For example, studies using the immune mediated models typified by
experimental allergic encephalitis (EAE), reviewed in detail in Gold, et al. [90], include genetic elements
of susceptibility and have allowed for the development of many of the current anti-inflammatory based
treatments for MS that are currently on the market. In general, these treatments reduce inflammatory
damage to the CNS and significantly enhance quality of life for people with MS, but do not effectively
promote myelin repair (reviewed in detail in [6]). In a large, prospective study of 471 people with
MS at one tertiary referral center, followed over a period of ten years, ultimate disease progression
and significant disability was seen in 59% of people, regardless of how they were treated [91]. It is
not surprising that therapies developed primarily using EAE models would fail to target myelin
repair, since, in these animals, myelin destruction is continuous and simultaneous with any repair
activity—either endogenous or therapeutically induced—making it difficult to assess the relative
contribution of control of pathology and repair.
The second major category of demyelinating disease models are those involving the delivery
of a gliotoxin that preferentially damages oligodendrocytes or other glia leading to demyelination.
These models include local injection of lysolethicin or ethidium bromide or systemic delivery of
cuprizone, and these models have the advantage that, once the toxin is removed, myelin undergoes
spontaneous recovery [92–94]. This characteristic has allowed for the identification of therapeutic
approaches that enhance myelin repair with little or no contribution from the immune system.
The limitation of these models, however, is that they generate transient demyelination that undergoes
spontaneous repair and as a result largely identify reagents that accelerate rather than initiate
myelin repair.
The third general category of demyelinating models are those that generate demyelination
through targeted ablation of oligodendrocytes. Several different paradigms have been developed
to selectively eliminate oligodendrocytes including metabolic poisoning using cell type targeting of
diphtheria toxin and the induction of cell type specific apoptosis through selective activation of the
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caspase cascade [95,96]. As yet, the use of such models has been restricted to mechanistic studies
and not the development of new therapeutic approaches. Using combinations of the model systems
discussed above, a number of myelin repair strategies have emerged. These include both cell-based
and molecular strategies that alone or in combination with immunomodulators hold promise to alter
the trajectory of CNS demyelinating conditions.
7. Therapies Promoting Remyelination
An extensive knowledge of mechanisms of demyelination over the past century, both from human
and animal models has led to speculation on the key stages of remyelination. From developmental
studies it seems likely that a key limiting step in myelin generation is probably going to be sufficient
supply of OPCs from which proliferation, migration, and differentiation will take place allowing
myelinating oligodendrocytes to start producing new myelin. This intricate and well-organized
process has been the subject of many recent reviews [97–99]. It is no surprise therefore that one of the
early regenerative approaches to treat demyelination revolved around re-stocking the tissues’ supply
of precursor cells. Some of these experimental therapies are described below.
7.1. Oligodendrocyte Progenitor Cells
One potential approach to promoting remyelination in the CNS is to increase the number of OPCs
that can develop into myelinating oligodendrocytes. OPCs have been derived from fetal and human
brain tissue [100,101], human embryonic stem cells (hESCs) [102,103], and more recently from human
induced pluripotent stem cells (hiPSCs) [104,105]. Advances in our understanding of the development
of oligodendrocytes in both rodent and human systems resulted in the identification of cell type
specific markers that allowed for the identification and isolation of relatively pure populations of OPCs.
Building on rodent data, expression of CD140a PDGFRa identified through the binding of mAB A133
allowed unambiguous identification of human OPCs [106]. Isolation procedures and immunoselection
processes from fetal tissue allowed for the generation of a cell population that could be expanded
through selective growth factor addition and assayed for the ability to promote myelination following
transplantation into selected animal models [100,101,107].
Following transplantation of human fetal or adult OPCs into immunocompromised myelin
deficient rodent hosts, the OPCs were capable of differentiating and generating myelinating
oligodendrocytes and astrocytes in the host brain [101,105,108]. These studies revealed a number of
unexpected findings. First, the timing of integration of human cells was relatively slow compared to
their rodent counterparts. Detection of human GFAP as a marker for astrocytes, or Myelin basic protein
as a marker for myelinating oligodendrocytes revealed that the expansion of the cells took greater
than 6 months. Second, although the host glia had populated the CNS prior to the expansion of the
transplanted human cells, they were replaced over time by the human cells. Third, although the human
cells were in a rodent environment they retained human cellular properties including a large size
and distinct morphology. In other experiments, OPCs derived from hESCs integrated, migrated, and
differentiated in the irradiated brain, producing cognitive and motor improvement [109]. More recently,
hiPSC-derived oligodendrocytes were tested in vivo in MBP-deficient shiverer mice, and were shown
to migrate and differentiate into myelinating cells. Together these studies demonstrated the capacity
of cells isolated from the developing human CNS to generate a spectrum of OPCs in myelin repair.
Translating these animal studies to the clinic is, however, challenging primarily due to the fact that the
source of cells for transplantation is controversial. Fetal human neural cells are not readily obtained
and have associated ethical issues, while OPCs derived from hESCs and/or hiPSCs are unproven
in terms of safety, stability and reproducibility. Second, transplantation of non-host derived OPCs
will require long term immunosuppression of the host to prevent rejection raising the potential for
opportunistic infections. Finally, as with any replacement therapy it is unclear if the transplanted cells
will suffer the same loss as endogenous host cells. Although these concerns are significant, the elegance
of simply replacing lost oligodendrocytes to promote remyelination is a conceptually attractive strategy,

Brain Sci. 2018, 8, 111

9 of 19

in particular for hypomyelinating leukodystrophies where oligodendrocyte loss or dysfunction is the
main pathological hallmark of the disease, and so replacement of defective oligodendrocytes would be
more relevant. In MS, on the other hand, the presence of multi-focal lesions precludes the use of cell
transplantation as an effective therapeutic strategy, since it would require the use of multiple injections.
7.2. MSCs in Myelin Repair
One stem cell population that has become increasingly attractive as a therapeutic for
demyelinating diseases is mesenchymal stem cells (MSCs). Originally, MSCs were described due
to their adhesive characteristics, the capacity to self-renew, and their ability to generate the major
mesenchymal lineages including bone, fat, and cartilage. However, more recently it has been
recognized that MSCs have profound immunomodulatory capacities and this has led to their
development as a therapeutic for a number of conditions including demyelinating diseases of the
nervous system [110–113]. Furthermore, and although the hypothesis that MSCs have the capacity to
generate cells of the CNS is somewhat controversial and has been refuted [114], studies from a number
of groups have demonstrated that in animal models of multiple sclerosis such as EAE, treatment with
MSCs does at least in part promote oligodendrogenesis through the release of trophic factors, leading
to enhanced functional remyelination [115–118]. Somewhat unexpectedly, MSCs derived from human
bone marrow were equally effective in modifying disease as those from mice suggesting that the
effector mechanisms are shared across species. Mechanistic analyses suggest that treatment with MSCs
altered the balance between TH1 and TH2 cells leading to a reduction in proinflammatory cytokines
such as TNFalpha and IL6, and an increase in anti-inflammatory cytokines such as IL10 [115,119,120].
In addition to their effects in modulating the immune system, MSCs have also been proposed to alter
the specification of neural stem cells. In the presence of MSCs or their conditioned media, cultures of
neural stem cells generate greater numbers of neurons and oligodendrocytes and reduced numbers
of astrocytes consistent with their ability to promote recovery in the setting of disease [121,122].
These observations from multiple laboratories led to a number of phase I/II clinical trials in which
autologous MSCs, mostly derived from bone marrow, were expanded in vitro and reinfused into
individuals with relapsing-remitting or secondary progressive MS who have not responded to other
disease modifying therapies [123,124]. In the majority of trials MSC infusion appeared relatively
safe, however little or no benefit was observed as a result of MSC treatment in striking contrast to
the benefits seen in mouse models [125–127]. Interestingly, an immediate immunomodulatory effect
was reported in one trial, where an increase in CD4+CD25+ regulatory cells, and a reduction in
the proportion of lymphocytes was seen [128]. A number of factors may explain the lack of MSC
efficacy in human clinical trials including dosage, route of delivery, cell viability and cellular source.
Evidence for evaluating the source of MSCs comes from studies suggesting that MSCs isolated from
people with MS are far less effective at reducing disease burden and promoting repair than naïve cells
when transplanted into animals with EAE [129]. Perhaps more compelling, bone marrow derived
MSCs isolated from animals with EAE also show greatly reduced efficacy to reduce disease burden
and promote repair when transplanted back into syngeneic EAE animals. Thus, the failure to see
improvement in the MS clinical trials may reflect the use of autologous MSCs. Cataloging the molecular
changes that occur in MSCs as a result of EAE reveal changes in more than 2000 genes mostly associated
with immune responses and neural development [130]. Given the magnitude of these changes the
future use of autologous MSCs for the treatment of MS is likely to be limited.
7.3. Bone Marrow Transplants
With advances in bone marrow stem cell ablation by chemotherapy and irradiation, several
studies have adopted bone marrow transplantation as a potential treatment for MS. Initial outcomes
from such approaches have been very encouraging with significant long-lasting reduction in disease
burden and functional deterioration [131–133]. The exact mechanism underlying their benefit is
not well understood. It seems likely, however, that the treatment results in a major resetting of the
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cellular repertoire of the immune system and with the deletion of CNS antigen-oriented T and B cells
the pathology of the disease is reduced. Whether this reduction in pathology is sufficient to allow
endogenous myelin repair in the CNS or it simply prevents further insults has yet to be determined.
There are, however, a number of concerns with bone marrow transplant approaches. First, the stem
cell depletion regime is very harsh and carries a significant risk particularly for individuals already
severely compromised by disease; in one multi-center cohort study of 281 individuals, transplant
related mortality was 2.8% within 100 days, and the overall survival at 5 years was 93% [131]. Second, it
is unclear whether over time CNS antigen directed T and B cells will reemerge resulting in a recurrence
of the disease. Third, the treatment is currently expensive and presumably negates prior immune
protection leaving recipients potentially susceptible to opportunistic infections. While bone marrow
transplantation may be an attractive option for some individuals with autoimmune diseases, more
targeted molecular therapies that promote myelin repair in the CNS are clearly needed.
7.4. Molecular Mediators of Myelin Repair
In many conditions, both in animal models and in humans, remyelination is quite effective and it
seems likely that demyelinating diseases largely become symptomatic when the pathologic disease
activity exceeds the capability of the tissue for repair. Such an imbalance may occur if the disease is
overwhelmingly severe, or the repair process is compromised. Analysis of post mortem tissue suggests
that in many cases of MS the process of myelin repair is compromised, and this has led to concerted
efforts to enhance remyelination through either modification of the lesion environment or enhancing
the capacity of OPCs to generate myelin in the adult animal. Currently, evidence supports the notion
that one of the rate limiting steps in myelin repair is the differentiation of OPCs into myelinating
oligodendrocytes. For example, distinct subpopulations of MS lesions contain demyelinated axons
adjacent to cells that have the characteristics of OPCs but have failed to differentiate and myelinate
nearby axons [20,67,134]. In the absence of myelination such axons are more vulnerable to damage
and loss of axons ultimately leads to irreversible functional loss.
Two general strategies can promote remyelination by oligodendrocytes. The first involves the
neutralization of inhibitory signals that block the formation of myelin by oligodendrocytes. Several
such signals have been identified including the expression of high levels of poly sialic acid on the
surface of axons and the expression of LINGO1 on OPCs and possibly axons. LINGO1 is a leucine
repeat rich cell surface molecule, initially identified in axons as part of the Nogo receptor complex
and has an inhibitory role in axon regeneration [135]. Its expression in oligodendrocytes is also
associated with negative regulatory effects, by way of limiting oligodendroglial differentiation and
myelination [135,136]. Inhibition of LINGO1 with specific antibodies promotes oligodendrocyte
differentiation, enhances myelination and reduces functional deficits in EAE [136,137]. Initial clinical
trials with anti-LINGO1 (opicinumab) have not been as successful as the animal models had
predicted [138,139]. Specifically, no difference was observed in remyelination as measured by full-field
visual evoked potentials (VEP) at 24 weeks. However, further refinement of patient selection and
treatment paradigms will likely provide increased benefit, and a new trial is underway to assess the
efficacy of opicinumab as an add-on therapy in relapsing remitting MS [140]. Another potential target
is the muscarinic acetylcholine receptors (mAChRs); their activation in cultured OPCs resulted in lower
expression of myelin protein in mature oligodendrocytes, and increased expression of PDGFRa, both
of which act to inhibit oligodendrocyte differentiation [141]. Consistent with this finding, benztropine,
an inhibitor of the muscarinic receptor, was identified in a high throughput screen utilizing purified
rat OPCs, and subsequently found to enhance remyelination and functional recovery in EAE and
cuprizone-induced demyelination models [142]. With the realization that oligodendrocytes are capable
of myelinating inert fibers of the correct size, an inert micro pillar approach also identified another
anti-muscarinic agent, clemastine, as a promoter of myelination [143]. Recent clinical trial data suggest
it may have some efficacy in MS, by showing shorter VEP latencies in the treatment group, a measure
of optic nerve remyelination [144]. Other less well developed signaling pathways with a negative
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regulatory role on oligodendrocyte maturation and myelination, such as the Wnt pathway, are still
being studied, and targeted therapeutic options are currently under development [145,146].
The second general approach deals with enhancement of pro-differentiation signals. With the
emergence of more highly developed stem cell technologies, a number of positive regulators of
oligodendrocyte development have been identified. For example, the ability to generate large numbers
of OPCs using epiblast derived or IPS cell technology has facilitated effective high through-put
screening that led to the identification of miconazole—an anti-fungal, and clobetasol—a glucocorticoid
receptor agonist, as promoters of oligodendrocyte differentiation [147]. In all cases, rodent remyelinating
systems have demonstrated that factors promoting oligodendrocyte differentiation also enhance the
rate of myelin repair in vivo.
Other therapies that have been studied recently address different aspects of oligodendrocyte
physiology in an effort to indirectly promote remyelination. For example, biotin is a cofactor for
essential carboxylases, one of which (acetyl-CoA carboxylase) is expressed in oligodendrocytes. It was
recently shown in people with progressive MS that high dose biotin has had a favorable effect on
functional disability [148]. It is still unclear whether the functional improvement was secondary to
myelin repair, which is thought to be secondary to fatty acid synthesis, or to axonal protection from
enhanced energy production.
8. Challenges to Developing Remyelinating Therapies
Efforts to identify remyelinating therapies in the CNS are still in their infancy. Compared to
the effort that has been committed to developing modulators of the immune system, relatively little
work has been focused on remyelination. Even with increased efforts, however, the barriers to success
are formidable. For example, much of the current work is focused on enhancing oligodendrocyte
differentiation, and yet the evidence that this is the primary rate limiting step in remyelination failure
in MS and other demyelinating diseases is circumstantial. Indeed, the agents currently identified in
a variety of screening studies appear to accelerate remyelination, but it is unclear whether they are
capable of initiating repair. This uncertainty stems in part from the lack of appropriate rodent models
for chronic demyelination. While EAE has been extremely useful for relapsing-remitting MS, there is
currently a lack of models of progressive, chronic MS.
An additional hurdle to developing effective repair strategies is the complexity of the pathology.
In addition to axons, cells of the oligodendrocyte lineage, and immune cells, multiple other cell types
are involved in both pathology and likely repair. These include astrocytes, microglia, pericytes, neural
stem cells, and cells of the vasculature. Developing therapies based on a single cell type response
misses the intrinsic complexity of the lesion that may dictate outcomes. Finally, issues of species
specificity and perhaps more importantly scale are critical for effective translation into the clinic.
While small lesions may repair effectively, once they attain a critical size repair may fail. Generating
models of large lesion size likely requires animal models other than rodents.
9. Conclusions
In recent years great progress has been made in developing new therapeutic approaches for
the treatment of demyelinating diseases. While there is a large number of different approaches to
the treatment of demyelinating diseases such as MS, the majority of these approaches are focused
on reducing the impact of the immune system in promoting the pathogenesis. However, none of
the currently available therapies is able to provide a cure or effectively terminate the pathology,
as evidenced by the propensity for recurrence of myelin loss and eventual functional decline.
There is a dire need for more targeted therapeutics that can restore myelin and protect demyelinated
axonal processes. One of the key advances of the last decade has to be our expanding knowledge
of some of the developmental mechanisms governing myelination, but more importantly also
spontaneous remyelination. We are unraveling a great deal of mystery pertaining to a once un-treatable
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demyelinating disease, MS, in humans with the hope that this will rapidly translate into new
effective therapies.
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